Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Fidaxomicin one of six drugs to gain SMC approval

By News team

Fidaxomicin is one of six drugs newly approved for use within NHS Scotland.

The Scottish Medicines Consortium has restricted the use of Astellas’s Clostridium difficile treatment — launched last month (June 2012) under the brand name Dificlir (PJ 2012;288:702) — to treating first recurrences of infection, and on specialist advice only.

Rufinamide (Inovelon; Eisai) is accepted for restricted use for patients who have failed treatment with, or are intolerant to, other antiepileptic drugs. "The oral suspension is bioequivalent to the tablets and provides an alternative formulation for patients who have difficulty swallowing. Depending on the dose it may be more expensive than the tablets, but any overall budget impact is likely to be small," the SMC says.

Also accepted for restricted use are the pulmonary arterial hypertension drug tadalafil (Adcirca; Eli Lilly) and golimumab (Simponi; Merck Sharp & Dohme) for its psoriatic arthritis indication.

Tadalafil treatment must be initiated by specialists, such as those in the Scottish Pulmonary Vascular Unit, and the drug must be made available under the agreed patient access scheme. Golimumab can only be used at a dose of 50mg and after at least two standard disease-modifying antirheumatic drugs have failed. The economic case was not demonstrated for the 100mg dose of golimumab, the SMC says.

Eplerenone (Inspra; Pfizer) is accepted for the treatment of chronic heart failure and left ventricular systolic dysfunction and pegylated interferon alfa-2b (Viraferon Peg; Merck Sharp & Dohme) for its paediatric indication. Thiotepa (Tepadina; Adienne) is not accepted for use.

Citation: The Pharmaceutical Journal URI: 11103994

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Dificlir pack shot

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.